HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the... |
Did you find an answer to your question?
Yes
No
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our medical information is accurate, up to date, and scientifically balanced.
XYNTHA® Lyophilized Powder (antihemophilic factor [Recombinant])
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our medical information is accurate, up to date, and scientifically balanced.
XYNTHA® Lyophilized Powder Quick Finder
Highlights
Indications and Usage
1 INDICATIONS AND USAGE
XYNTHA, Antihemophilic Factor (Recombinant), is indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:
- On-demand treatment and control of...
Did you find an answer to your question?
Yes
No
Dosage and Administration
2 DOSAGE AND ADMINISTRATION
For intravenous use after reconstitution only.
2.1 Dose
- Dosage and duration of treatment depend on...
Did you find an answer to your question?
Yes
No
Dosage Forms and Strengths
3 DOSAGE FORMS AND STRENGTHS
XYNTHA is available as a white to off-white lyophilized powder in the following nominal dosages:
- 250 International Units
- 500 International Units
- 1000...
Did you find an answer to your question?
Yes
No
Contraindications
4 CONTRAINDICATIONS
XYNTHA is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster proteins.
...
Did you find an answer to your question?
Yes
No
Warnings and Precautions
5 WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity Reactions
Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with XYNTHA. Inform patients...
Did you find an answer to your question?
Yes
No
Adverse Reactions
6 ADVERSE REACTIONS
The most common adverse reactions (≥10%) with XYNTHA in adult and pediatric previously treated patients (PTPs) were headache, arthralgia, pyrexia, and cough.
...
Did you find an answer to your question?
Yes
No
Use in Specific Populations
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
It is not known whether...
Did you find an answer to your question?
Yes
No
Description
11 DESCRIPTION
The active ingredient in XYNTHA, Antihemophilic Factor (Recombinant), is a recombinant antihemophilic factor (rAHF), also called coagulation factor VIII, which is produced by recombinant DNA technology. It is...
Did you find an answer to your question?
Yes
No
Clinical Pharmacology
...
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
XYNTHA temporarily replaces the missing clotting factor VIII that is needed for effective hemostasis.
Did you find an answer to your question?
Yes
No
Nonclinical Toxicology
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies have been conducted with XYNTHA to assess its mutagenic or carcinogenic...
Did you find an answer to your question?
Yes
No
Clinical Studies
14 CLINICAL STUDIES
Three completed multicenter, open-label studies support the analysis of safety and efficacy of XYNTHA in on-demand treatment and control of bleeding episodes and perioperative management, and routine...
Did you find an answer to your question?
Yes
No
References
15 REFERENCES
- Nilsson IM, Berntorp EE and Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost. 1993;70(1):56–59.
- Hoyer LW. Hemophilia A....
Did you find an answer to your question?
Yes
No
How Supplied/Storage and Handling
16 HOW SUPPLIED/STORAGE AND HANDLING
How Supplied
Each XYNTHA Vial Kit contains: one prefilled diluent syringe containing 4 mL 0.9...
Did you find an answer to your question?
Yes
No
Medication Guide
17 PATIENT COUNSELING INFORMATION
Advise patients to:
- read the FDA-approved patient labeling (Patient Information and Instructions for Use).
- report any adverse reactions or problems that concern them when...
Did you find an answer to your question?
Yes
No
Instructions For Use
Instructions for Use
XYNTHA® /ZIN-tha/
[Antihemophilic Factor (Recombinant)]
XYNTHA is supplied as a...
Did you find an answer to your question?
Yes
No
Did you find an answer to your question?
Yes
No
Resources
Didn’t find what you were looking for? Contact us.
To interact with the Medical Information Digital Assistant click here.
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Report Adverse Event
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at(800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.
(800)-332-1088.